INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY

Han Zhang, Zheli Liu, Peng Sun, Feng GuRetina 2012 · DOI

Abstract

Intravitreal bevacizumab is well tolerated and improves best-corrected visual acuity in choroidal neovascularization secondary to punctate inner choroidopathy over a 12-month period.
BibTeX
@inproceedings{zhang2012intravitreal,
  author = {Han Zhang and Zheli Liu and Peng Sun and Feng Gu},
  title = {{INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY}},
  booktitle = {Retina},
  year = {2012},
  doi = {10.1097/iae.0b013e318242b9da},
}

Loading related content...

Figure